Park Medi World Ltd Directors Report

Dear Members,

The Board of Directors of Park Medi World Limited (Company) have immense pleasure in presenting the 15 th Boards Report on the business and operations of the Company, together with the Audited Financial Statements and the Auditors report of the Company for the financial year (FY) ended on March 31,2026.

Financial Highlights

Key highlights of the financial results of the Company prepared as per the Indian Accounting Standards (Ind AS) for the financial year ended March 31, 2026, along with corresponding numbers of the previous financial year ended March 31,2025, are as under:

(INR in Million)

Particulars	Standalone		Consolidated
	FY 2025-26	FY 2024-25	FY 2025-26	FY 2024-25
Revenue from operations	1,290	916	16,794	13,936
Other income	103	21	316	324
Total Income	1,393	937	17,110	14,260
Cost of Material/Services Purchased	158	162	2,951	2,824
Employee benefits	187	172	3,234	2,757
Finance Costs	128	123	589	608
Professional & Consultation fees	102	100	2,571	2,082
Depreciation and Amortization	45	49	625	569
Other expenses	323	241	3,588	2,566
Total Expenses	939	848	13,564	11,403
Profit before exceptional items & tax	454	89	3,546	2,857
Profit before tax	454	89	3,546	2,857
Total comprehensive Income	368	73	2,745	2,162
Basic and diluted earnings per share (in H)	1	0.19	7	6

State of the Companys affairs

(INR in Million)

Particulars (in INR mn)	FY 25-26	FY 24-25	YoY Growth%
Bed Capacity	3,610	3,000	20.3%
Occupancy (%)	64.1%	61.6%	244 bps
ARPOB (INR)	28,005	26,206	6.9%
Total Patients	873,356	719,163	21.4%
EBITDA (ex Other income)	4,443	3,710	19.8%
PAT Margin (%)	16.3%	15.5%	83 bps

The Group has reported, on consolidated basis, total income ol INR 17,110 million (mn) in FY 2025-26 with profit of INR 3,546 mn vis-a-vis income of INR 14,260 mn with profit of INR 2,857 mn in FY 2024-25. During FY 2025-26, there was no change in the nature of the business of the Company.

Park Group of Hospitals is North Indias 2 nd largest Hospital Chain, currently operating an extensive network of 16 hospitals strategically located across North India with a combined capacity of 3,960 beds. Primarily, each hospital is managed by a dedicated separate legal entity to ensure efficient operations and quality service. The map below provides a visual overview of these operational and upcoming hospital locations, along with their bed capacity.

Initial Public Offering and Listing

FY 2025-26 turned out to be one of the most important years in our journey so far. During the year, the Company has successfully completed its Initial Public Offering (IPO) of 5,67,90,123 Equity Shares comprising a fresh issue of 4,75,30,864 Equity Shares and an offer for sale, by one of the existing Promoters of 92,59,259 Equity Shares at an offer price of INR 162/- per equity share (including a premium of INR 160/- per share).

The IPO was opened on December 10, 2025 and closed on December 12, 2025 (both days inclusive). Subsequently, the Equity Shares of the Company were listed and admitted for trading on the BSE Limited and the National Stock Exchange of India Limited with effect from December 17, 2025.

The Monitoring Agency, CRISIL Ratings Limited, submits its report on a quarterly basis, outlining any deviation(s) or variation(s), if any, in the utilization of the public issue proceeds. These reports are reviewed by the Audit Committee in its meetings and are thereafter submitted to the Stock Exchanges as per the applicable regulatory requirements. There has been no deviation in the utilization of the IPO proceeds of the Company as on the date of this report.

Material Events during the year Acquisitions

During the FY 2025-26, the Company has made the following acquisitions:

1. On June 12, 2025, Aggarwal Hospital and Research Services Private Limited, a wholly-owned subsidiary of the Company, entered into a share purchase agreement (SPA) and acquired 55% of the paid-up equity share capital of Devina Derma Private Limited. Subsequently, on August 23, 2025, the parties entered into an Addendum to said SPA to acquire whole shareholding of Devina Derma Private Limited.

2. On December 19, 2025, the Company approved the acquisition of KP Institute of Medical Sciences (KPIMS), Agra, with a capacity of 360 beds, through the purchase of 100% of the existing shareholding of K P S Wellness Private Limited and SVPD Healthcare Private Limited and successfully completed the said acquisitions on January 30, 2026, and March 20, 2026, respectively.

3. On December 23, 2025, Blue Heavens Health Care Private Limited, a wholly-owned subsidiary of the Company has completed the acquisition of Durha Vitrak Private Limited which owns Febris Multi-speciality Hospital with a capacity of 200 beds. The said acquisition has been completed pursuant to the approval of resolution plan by the Honble National Company Law Tribunal, New Delhi, under the corporate insolvency resolution process in accordance with the Insolvency and Bankruptcy Code, 2016.

4. On January 5, 2026, the Company has acquired 100% of the existing shareholding of Mahip Hospitals Private Limited which operates the Krishna Super-Speciality Hospital in Bhatinda with a capacity of 250 beds. The Company had been managing the operations of this hospital since July 2025 through a separate agreement.

Capacity Expansion

On March 10, 2026, R G S Healthcare Limited, a subsidiary of the Company, approved the expansion of bed capacity of Grecian Super Speciality Hospital, Mohali by adding 150 beds to the existing bed capacity of 350 beds.

The upcoming 150-bed super speciality expansion at Mohali will focus on strengthening advanced clinical capabilities, with investments directed toward key high-acuity specialties including Oncology, Neurosciences, Gastro Sciences, and Robotic Surgeries. The expansion will also introduce robotic joint replacement capabilities, significantly enhancing the hospitals ability to deliver cutting-edge, minimally invasive treatment options.

Transfer to Reserves

The Company does not propose to transfer any amount to any reserve and the entire amount of the profit for FY 2025-26 shall form part of retained earnings.

Dividend

The Board of Directors (Board) does not recommend any dividend on the equity shares of the Company for the financial year ended March 31, 2026.

The Dividend Distribution Policy, in terms of Regulation 43A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) is available on the Companys website at

Deposit

The Company neither has any outstanding deposits nor it has accepted any deposits from the public during FY 2025-26.

Transfer of unclaimed dividend to Investor Education and Protection Fund

Since no dividend was declared during the year, therefore there has been no amount which was required to be transferred to the Investor Education and Protection Fund.

Credit Rating

The Companys commitment to financial discipline and prudence is evident from the strong credit ratings assigned by

rating agencies. The Companys long-term banking facilities are rated as Crisil A+/Stable by CRISIL Ratings Limited.

Subsidiaries, Joint Ventures and Associate Companies and their performance

As on March 31,2026, the Company has 22 subsidiaries including step-down subsidiaries. There are 7 Material Subsidiaries of the Company as per the Listing Regulations as on March 31, 2026.

During FY 2025-26, the following Companies become the Subsidiaries of the Company:

1. Mahip Hospitals Private Limited - wholly owned subsidiary

2. K P S Wellness Private Limited - wholly owned subsidiary

3. SVPD Healthcare Private Limited - wholly owned subsidiary

4. Devina Derma Private Limited - step down subsidiary

5. Durha Vitrak Private Limited - step down subsidiary

As on March 31, 2026, the Company has no holding, joint venture or associate company.

In terms of the requirements of Section 129(3) of the Companies Act, 2013, as amended from time to time (Act) , a statement containing salient features of the financial statements of the Companys subsidiaries is provided in note no. 56 of the consolidated financial statement.

The financial statements of the Company and its subsidiaries for FY 2025- 26 have been prepared in compliance with the applicable provisions of the Act and the Listing Regulations as well as in accordance with the Companies (Indian Accounting Standards) Rules, 2015. The audited standalone and consolidated financial statements together with the Independent Auditors Report thereon form part of this Annual Report.

The standalone and consolidated audited financial statements of the Company are available on the Companys website at . The financial statements of the subsidiaries, are available on the Companys website at

Share Capital

The authorised share capital of the Company as on March 31, 2026 is INR 125,00,00,000 (Indian Rupees One Hundred and Twenty-Five Crores only) divided into 62,50,00,000 (Sixty-Two Crore and Fifty lakhs) Equity Shares of INR 2 each.

The issued, subscribed and paid-up equity share capital as on March 31, 2026 is INR 86,38,61,728 (Indian Rupees Eighty- Six Crore Thirty-Eight Lakh Sixty-One Thousand and Seven Hundred Twenty- Eight only) consisting of 43,19,30,864 equity shares of face value of INR 2 each.

During the year, the issue, subscribed and paid-up equity share capital of the Company were increased pursuant to the IPO of the Company as briefed herein.

Auditors and Auditors Report Statutory Auditor

The Company, in its 13 th Annual General meeting (AGM) appointed M/s Agiwal & Associates, Chartered Accountants, (Firm Registration Number: 000181N) as Statutory Auditors of the Company for a period of 5 (Five) consecutive years commencing from the conclusion of 13 th AGM until the conclusion of 18 th AGM of the Company to be held in the year 2029 for the FY 2028-29.

There were no observations made by the Statutory Auditors in their report and the explanations given by them are self-explanatory.

The Auditors Report on the standalone and consolidated financial statements of the Company for FY 2025-26 forms part of this Annual Report.

Internal Auditor

NKSC & Co., Chartered Accountants, was appointed as the Internal Auditor of the Company for the financial year ended March 31, 2026 and the report given by the Internal Auditor has been reviewed by the Audit Committee from time to time.

On the recommendation of the Audit Committee, the Board at its meeting held on May 15, 2026 had approved the appointment of NKSC & Co., Chartered Accountants, as the Internal Auditor of the Company for the financial year ending March 31, 2027.

Secretarial Auditor

Pursuant to the extant provisions of Section 204 of the Act, SBR & Co. LLP, Practicing Company Secretaries, were appointed as Secretarial Auditor of the Company for FY 2025-26.

Further, as per Regulation 24A of the Listing Regulations, the material unlisted subsidiaries of the Company as on March 31, 2026 viz. Aggarwal Hospital and Research Services Private Limited, Blue Heavens Health Care Private Limited, Park Medicity India Private Limited, Narsingh Hospital & Heart Institute Private Limited, Park Medicenters and Institutions Private Limited, R G S Healthcare Limited and Umkal Healthcare Private Limited have also undertaken a secretarial audit for the FY 2025-26.

The Secretarial Audit Reports of the Company and its material subsidiaries in Form MR-3 for the FY 2025-26 have been provided herein as Annexure-I of this report. The Secretarial Audit reports are unqualified and does not contain any observation.

Pursuant to Regulation 24A of the Listing Regulations, the Board on the recommendation of the Audit Committee in its meeting held on May 15, 2026, has appointed SBR & Co. LLP, Company Secretaries in Practice, (LLPIN: AAO-9057), as the Secretarial Auditors of the Company for a period of five consecutive financial years from 2025-26 to 2029-30. The said appointment is subject to shareholders approval at the ensuing 15 th AGM of the Company.

SBR & Co. LLP, have confirmed that they are not disqualified to be appointed as a Secretarial Auditors and are eligible to hold office as Secretarial Auditors of the Company.

Cost Auditors

Pursuant to the provisions of Section 148 of the Act read with the Companies (Cost Records and Audit) Rules, 2014 and the rules made thereunder, Bahuguna & Co., Cost Accountants, was appointed as Cost Auditor of the Company for the FY 2025-26. Cost Auditors will submit their report for FY 2025-26 within the timeframe prescribed under the Act.

The Board on the recommendation of the Audit Committee at its meeting held on May 15, 2026, appointed Sachin Gupta & Co. as the Cost auditor for FY 2026-27 subject to ratification of remuneration payable to said Cost Auditor by the shareholders in ensuing AGM.

Fraud Reporting

During the year under review, the Statutory Auditor and Secretarial Auditor of the Company have not reported any instances of frauds committed in the Company by its Officers or Employees, to the Audit Committee, as required under Section 143 (12) of the Act.

Meeting of Board of Directors

The Board met 15 (fifteen) times during the FY 2025-26. The intervening gap between the two Board Meetings did not exceed 120 days, as prescribed under the Act. The details of board meetings and the attendance of the Directors are provided in the Corporate Governance Report, which forms part of this Annual Report.

Committees of the Board

The Committees of the Board play a significant role in strengthening the Companys governance framework by providing focused oversight and effective supervision over specific functional areas. These committees are constituted in accordance with the requirements of the Act and Listing Regulations.

The minutes of the meetings of all Committees are placed before the Board for its noting and review. The meetings of the Committees are generally convened prior to the meetings of the Board, wherever required, and the respective Chairpersons of the Committees apprise the Board of the key deliberations, recommendations, and decisions taken at such meetings.

The committees submit their recommendations to the Board for approval, and during the year, all the recommendations by the committees were approved. When needed, committees may also invite special guests to their meetings.

As on March 31, 2026, the Board has six Committees as follows:

1. Audit Committee

2. Nomination and Remuneration Committee

3. Stakeholders Remuneration Committee

4. Corporate Social Responsibility (CSR) Committee

5. Risk Management Committee

6. IPO Committee

Details relating to the composition of the Committees, their terms of reference, number of meetings held, attendance of members at such meetings, and other requisite information are provided in the Corporate Governance Report forming part of this Annual Report.

Audit Committee

The Audit Committee comprises of three members - Mr. Ravi Krishan Takkar as Chairman, Dr. Ajit Gupta and Dr. Kamlesh Kohli as members of the Committee. All the recommendations made by the Audit Committee were accepted by the Board.

Corporate Social Responsibility

The CSR Committee of the Company is inter alia responsible for formulating, recommending and monitoring the CSR Policy of the Company which contains the approach and direction given by the Board, and includes guiding principles for selection, implementation and monitoring of activities as well as formulation of the annual action plan.

The composition of the CSR Committee, and other details including brief outline of the CSR Policy of the Company, the amount that the Company was required to spent in terms of the provisions of the Act, and the amount that was actually spent during the FY 2025-26 are set out in Annexure-II to this Report in the format as prescribed under the Companies (Corporate Social Responsibility Policy) Rules, 2014.

Performance Evaluation

Pursuant to the provisions of the Act and the Listing Regulations, the Nomination and Remuneration Committee has put in place a framework for annual evaluation of the performance of the Board of Directors, Board Committees and individual directors, including the Independent Directors and Chairperson of the Company. The Board evaluation was conducted through questionnaire designed with qualitative parameters and feedback based on ratings. For the FY 2025-26, the evaluation process was undertaken in accordance with the abovementioned framework and applicable law. The Board expressed their satisfaction with the evaluation process.

Policy on Directors Appointment and Remuneration

The Board and Nomination and Remuneration Committee reviewed the performance of the individual directors on the basis of the criteria such as the contribution of the individual director to the Board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings, willingness to devote time and effort to understand the Company and its business by the Directors, competency to take the responsibility and having adequate qualification, experience and knowledge, quality and value of their contributions at board meetings, effectiveness, leadership quality of the Chairperson etc. The requisite policies with respect to the above for Directors and Key Managerial

Personnel are available on the website of the Company at .

Employee stock option scheme

Pursuant to Board and Shareholders resolutions dated March 11, 2025, and March 14, 2025, respectively, the Company has adopted Park - Employees Stock Option Scheme-2025 (ESOP Scheme) . The Scheme permits grants of stock options to employees of the Company and its subsidiaries, not exceeding 1% of the Companys paid-up capital.

The objectives of the ESOP Scheme are inter alia to attract and retain talent, incentivize employee performance, align employee interests with long-term shareholder value, promote sustained growth, and offer a variable pay structure through deferred rewards.

The ESOP Scheme is in compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

No options have been granted under ESOP Scheme.

The Company has obtained certificate(s) from its Secretarial Auditor in accordance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and the resolution(s) passed by the members of the Company. The said certificate will be made available for electronic inspection by the members during the AGM. The requisite disclosures have been made on the website of the Company.

Material changes and commitment affecting the financial position of the Company occurred between the end of the financial year to which these financial statements relate and the date of the report

There has not been any such instance to report except the below.

On April 10, 2026, as per its commitment for healthcare expansion, the Company inaugurated its state-of-the-art multisuper speciality hospital in Panchkula. This facility has been strategically developed to cater to the burgeoning demand for tertiary and quaternary healthcare services across the catchment regions of Haryana, Punjab, Himachal Pradesh, and Chandigarh. Equipped with specialized treatment capabilities across multiple clinical disciplines, the hospital is well-positioned to meet the

/ regions escalating need for advanced and comprehensive medical care. By bringing world-class healthcare infrastructure closer to patients in these regions, the hospital is expected to significantly reduce patients dependence on metro cities for accessing high-end medical treatment.

l

Independent Directors Meeting

5 The Independent Directors met once on December 04, 2025, U without the attendance of Non-Independent Directors and members of the management. The Independent Directors reviewed the performance of Non-Independent Directors, t the Committees and the Board as a whole along with the performance of the Chairman of the Company, taking into account the views of Executive Directors and Non-Executive Directors and assessed the quality, quantity and timeliness of flow of information between the management and the Board that is necessary for the Board to effectively and reasonably perform their duties.

Directors & Key Managerial Personnel l Board of Directors

As on March 31, 2026, the Companys Board had Six members comprising of three Executive Directors, three Non-Executive and Independent Directors including one Woman Director.

The details of Board and Committee composition, tenure of directors, meetings and other details are available in the Corporate Governance Report, which forms part of this Annual Report.

I There was no change in the Board of Directors of the Company

f Retirement by Rotation

Pursuant to Section 152 of the Act, Dr. Sanjay Sharma (DIN: . 07181328), Whole-time Director, retires by rotation at the ensuing

AGM and being eligible offers himself for re-appointment. The Board on the recommendation of Nomination and Remuneration Committee, recommends his re-appointment.

l

r Remuneration to Executive Directors

* During FY 2025-26, the Executive Directors of the . Company have received remuneration from the Company and following Subsidiaries:

(INR in Million)

Name	Name of Subsidiary	Amount
	Narsingh Hospital & Heart Institute Private Limited	110
	Park Medicity India Private Limited	107.5
	Park Medi World Limited	2.5
Dr. Ajit Gupta	Park Medicenters and Institutions Private Limited	15
	Blue Heavens Health Care Private Limited	20
	Umkal Healh Care Private Limited	20
	Aggarwal Hospital and Research Services Private Limited	12.5
	Park Medicity (North) Private Limited	12.5
	Narsingh Hospital & Heart Institute Private Limited	22.5
	Park Medicity India Private Limited	20
	Park Medi World Limited	2.5
Dr. Ankit Gupta	Park Medicenters and Institutions Private Limited	102.5
	Blue Heavens Health Care Private Limited	20
	Umkal Healh Care Private Limited	20
	Aggarwal Hospital and Research Services Private Limited	12.5
	Park Medicity (North) Private Limited	100
Dr. Sanjay Sharma	Aggarwal Hospital and Research Services Private Limited	15.88

Key Managerial Personnel

Pursuant to Section 2(51) and 203 of the Act, following are the Key Managerial Personnel of the Company as on March 31,2026:

1. Dr. Ajit Gupta, Whole Time Director

2. Dr. Ankit Gupta, Managing Director

3. Dr. Sanjay Sharma, Whole-time Director & Chief Executive Officer

4. Mr. Rajesh Sharma, Chief Financial Officer

5. Mr. Abhishek Kapoor, Company Secretary &

Compliance Officer

There were no changes in the Key Managerial Personnel of the Company during FY 2025-26.

Declaration by Independent Directors

The Company has received declaration from the Independent Directors that they meet the criteria of independence as provided in section 149(6) of the Act read with Regulation 16(1) (b) of the Listing Regulations and there has been no change in the circumstances which may affect their status as Independent Director of the Company. Since, none of the Independent Directors has completed their tenure of appointment therefore no Independent Director has been proposed for reappointment.

Further, they have confirmed that their names are registered in the databank maintained with the Indian Institute of Corporate Affairs (IICA) in accordance with the provisions of section 150 of the Act.

Based on the disclosures received, the Board is of the opinion that, all the Independent Directors fulfil the conditions specified in the Act and Listing Regulations and are independent of the management.

Directors Responsibility Statement

Pursuant to Section 134(5) of the Act, the Board of Directors to the best of their knowledge and based on the information and explanations received from the Company, confirm that:

a. In the preparation of the annual accounts, the applicable accounting standards have been followed and there are no material departures;

b. The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that period;

c. The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d. The Directors have prepared the annual accounts on a going concern basis;

e. The Directors have laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and operating effectively; and

f. The Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

Registered Office

There has not been any change in registered office

of the Company.

Details of significant & material orders passed by the regulators or courts or tribunal impacting the going concern status and Companys operations in future

During FY 2025-26, there has been no such order impacting the going concern status and Companys operations in future.

Annual Return

In accordance with Section 92(3) read with Section 134(3)(a) of the Act and the Companies (Management and Administration) Rules, 2014, the Annual Return of the Company in Form MGT-7, is available on the Companys website at .

Particulars of Employee and Remuneration

The information required under Section 197(12) of the Act read with rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, relating to percentage increase in remuneration and the ratio of remuneration of each Director and Key Managerial Personnel to the median of employees remuneration are provided in Annexure-III of this report.

The statement containing particulars of employees, as required under Section 197(12) of the Act read with rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is provided in a separate annexure forming part of this report. However, in terms of Section 136 of the Act, the Annual Report is being sent to the shareholders and others entitled thereto, excluding the said annexure, which is available for inspection by the shareholders at the Registered Office of the Company during business hours on working days of the Company. Any member interested in obtaining a copy of the same may write to the Company Secretary.

Vigil Mechanism and Whistle Blower Policy

The Company has adopted a Vigil mechanism and whistle blower policy and has established the necessary vigil mechanism for the Directors and employees to report concerns about any unethical behavior, actual or suspected fraud or violation of the Companys Code of Conduct as per the requirements of Section 177 of the Act and Regulation 22 of the Listing Regulations. No person has been denied access to the Chairman of Audit Committee and the Audit Committee. The said policy is available on the website of the Company at .

Risk Management

The Board has constituted a Risk Management Committee to identify risks across various areas of operations and to formulate appropriate risk mitigation strategies and policies. The Risk Management Committee periodically apprised the Board of Directors of the risk assessment and mitigation procedures undertaken. In the opinion of the Committee, no risks were identified that could materially threaten the existence or operations of the Company. Details of the Risk Management Committee are provided in the Corporate Governance Report.

Internal Control Systems and Internal Financial Control

The Companys internal control systems are commensurate with the nature of its business, size and complexity of its operations. For strengthening the internal control system, the Company has well established internal audit. The internal audit is carried out by external independent auditor. Those controls are tested and certified by Internal Auditors.

Significant audit observations and follow up actions thereon, if any, are reported to the Board. The Board of Directors reviews adequacy and effectiveness of the Companys internal control environment and monitors the implementation of audit recommendations. During FY 2025-26, no reportable material weaknesses in controls were observed.

Particulars of Loans, Guarantees or Investments made under section 186 of the Companies Act, 2013

The details of loans, guarantees and investments for FY 2025-26 are disclosed in the notes to the standalone financial statements of the Company.

Particulars of Contracts or Arrangements made with related parties

All transactions with the related parties are placed before the Audit Committee for its prior approval. An omnibus approval from Audit Committee is obtained for the related party transactions which are repetitive in nature.

All transactions with related parties entered into during FY 202526 were at arms length basis and in the ordinary course of business, in accordance with the provisions of the Act and the rules made thereunder, Listing Regulations and the Companys Policy on Related Party Transactions. Accordingly, the prescribed Form AOC-2 is not applicable to the Company for FY 2025-26 and hence does not form part of this report. Members may refer to Notes of the Standalone Financial Statement which sets out Related Parties Disclosures.

Pursuant to the provisions of the Listing Regulations there were no materially significant Related Party Transactions during the FY 2025-26. Also, in terms of regulation 23 of the Listing Regulations, the Company has filed half yearly reports to the stock exchanges, for the related party transactions.

The Policy on Related Party Transactions is available on the Companys website at: .

Disclosures under Sexual Harassment of Women at Workplace (Prevention, Prohibition& Redressal) Act, 2013

The Company is in compliance with provisions relating to the constitution of Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

During FY 2025-26, the status of complaints received under Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 is provided below:

Particulars	No. of Complaints
No. of complaints filed during the FY 2025-26	Nil
No. of complaints disposed during the FY 2025-26	Nil
No. of complaints pending during the FY 2025-26	Nil

Disclosure under the pending proceedings under the Insolvency and Bankruptcy Code, 2016

No applications or proceedings initiated or pending against the Company under the Insolvency and Bankruptcy Code, 2016.

Details of difference between amount of the valuation done at the time of one-time settlement and the valuation done while taking loan from the banks or financial institutions

During the FY 2025-26 there was no one time settlement executed by the Company with any Bank or Financial Institution.

Conservation Of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

Conservation of energy and Technology Absorption

The operations of the Company are not energy intensive. Nevertheless, the Company remains committed to minimizing the environmental impact of its operations and continues to undertake initiatives aimed at enhancing sustainability. The hospitals under Park Group have adopted environmentally friendly and energy-efficient equipment and in the ordinary course of business, continue to implement technologies and equipment that promote improved energy efficiency.

The Group also promotes responsible consumption practices through regular monitoring of energy usage, preventive maintenance of medical and non-medical equipment and adoption of energy-efficient lighting and infrastructure wherever feasible. Continuous efforts are undertaken to ensure proper biomedical waste management and adherence to applicable environmental and healthcare regulations.

The Company is investing regularly in maintenance and upgradation of equipment used at the hospitals. Park Group strives to deploy the best practices and best of technology available in the operations.

Foreign Exchange Earnings And Outgo

During FY 2025-26, there was an outflow of INR 2,93,61,491 in foreign exchange and there was no income in foreign exchange.

Secretarial standards

Company is in compliances with the secretarial standards issued by the Institute of Company Secretaries of India (ICSI) on Meeting of the Board of Directors (SS - 1) and General Meeting (SS - 2).

Maternity benefit provided by the company under maternity benefit Act 1961

During FY 2025-26, the extant provisions of the Maternity Benefit Act, 1961, were applicable to the Company and have been duly complied with.

All eligible women employees have been extended the statutory benefits prescribed under the Act, including paid maternity leave, continuity of salary and service during the leave period, and post-maternity support such as nursing breaks and flexible return-to-work options, as applicable. The Company remains committed to fostering an inclusive and supportive work environment that upholds the rights and welfare of its women employees in accordance with applicable laws.

Board Policies

The details of various policies approved and adopted by the Board as required under the Act and Listing Regulations are available on the website of the Company at .

Corporate Governance Report

The Company is committed to good corporate governance practices. The Corporate Governance Report, as stipulated by Listing Regulations, forms part of this Annual Report along with the required certificate from a Practicing Company Secretary, regarding compliance of the conditions of Corporate Governance norms.

In compliance with corporate governance requirements as per the Listing Regulations, the Company has formulated and implemented a Code of Conduct for all Board members and senior management personnel of the Company (Code of Conduct) , who have affirmed the compliance thereto.

The Code of Conduct is available on the website of the Company at .

Business Responsibility and Sustainability Report

For the FY 2025-26, the Business Responsibility and Sustainability Report under the Listing Regulations is not applicable to the Company.

Management Discussion and Analysis

The Management Discussion and Analysis Report for the FY 2025-26, as stipulated under the Listing Regulations, is presented in a section forming part of this Annual Report.

Acknowledgement

The Board places on record its deep sense of appreciation for the committed services by all the employees of the Company. The Board would also like to place on record their appreciation to financial institutions, bankers and business associates, for their assistance, cooperation and encouragement extended to the Company.

	For and on behalf of the Board of Directors Park Medi World Limited
Date: May 15, 2026 Place: Gurugram	Dr. Ajit Gupta Chairman & Whole Time Director DIN: 02865369